Analgesic Selection in Advanced CKD, Heart Failure, and Anticoagulation

Ibuprofen - stop. Three independent contraindications converge:

• CKD stage 4: prostaglandin inhibition reduces afferent arteriolar dilation, causing acute kidney injury and hyperkalemia on a background of reduced reserve.
• HFrEF: sodium and water retention plus blunting of diuretic response - a recognized cause of decompensation.
• Warfarin: antiplatelet effect plus gastric mucosal injury raises bleeding risk, and the INR drift from 2.4 to 3.4 is consistent with this interaction. Add sacubitril–valsartan and furosemide, and this is the classic "triple whammy" combination for AKI.

Gabapentin - reduce. For eGFR 15–29, total daily dosing is in the range of 200–700 mg; 900 mg/day exceeds renal clearance capacity, explaining the sedation and dizziness. Gabapentinoids also cause peripheral edema, which is especially unwelcome in HFrEF. Either reduce to 100–300 mg daily, switch to renally adjusted pregabalin (25–50 mg/day), or stop if there is no clear neuropathy benefit.

Warfarin - notify the anticoagulation service today. INR 3.4 with a plausible precipitant requires a dose adjustment decision and a bleeding review, not a silent note in the chart. Check potassium and creatinine, since the NSAID exposure may already have caused injury.

Knee osteoarthritis

• Acetaminophen 1 g three times daily (max 3 g/day in an older adult) - no renal or cardiac contraindication; modest but real effect.
• Topical diclofenac 1% gel, 4 g four times daily to the knee - systemic exposure is roughly 6% of oral, so renal and cardiac risk is far lower, but monitor INR and renal function, and avoid if the skin is broken.
• Intra-articular corticosteroid (e.g., triamcinolone 40 mg) every 3 months as needed - effective, avoids systemic NSAID exposure; check INR within 24–48 hours given warfarin.
• Physical therapy, cane, and weight management - the interventions with the best durability.
• Oral NSAIDs: contraindicated. Duloxetine: not recommended at eGFR below 30.

Diabetic peripheral neuropathy

• Renally dosed gabapentinoid, as above, after correcting the current excess.
• Topical lidocaine 5% patch for the most painful foot area - negligible systemic absorption; useful when systemic options are constrained.
• Capsaicin as an adjunct; counsel on initial burning.
• Tricyclic (nortriptyline) only with caution: anticholinergic and cardiac conduction effects in a patient with HFrEF and polypharmacy.
• Address B12, glycemic control, and fall risk, which the dizziness has already raised.

Sequencing matters more than the list: fix the harms first, then layer in agents one at a time so that sedation and edema can be attributed.

Answer the question he actually asked, rather than deflecting to "opioids are bad."

Explain that tramadol is not a gentler option in his case:

• It is a prodrug requiring hepatic activation to an active metabolite that is renally cleared; at eGFR 26 it accumulates, raising the risk of sedation and seizures.
• It has serotonergic and noradrenergic activity, so it can precipitate serotonin syndrome with other serotonergic agents and causes SIADH/hyponatremia, particularly with diuretics.
• It potentiates warfarin, further destabilizing an INR that is already high.
• Its analgesia is modest - roughly comparable to codeine plus acetaminophen in many trials - so the risk-to-benefit ratio is unfavorable at his renal function.

Then offer a concrete alternative rather than a refusal: "Here is what I can do today" - stop the ibuprofen, correct the gabapentin dose, start acetaminophen and topical therapy, arrange an intra-articular knee injection, and reassess in two weeks. Patients accept "no" when it comes attached to a plan. Also confirm he understands to report black stools, bruising, or reduced urine output.